Using brain stimulation to help people with schizophrenia quit smoking
Official title: Circuitry-Guided Smoking Cessation in Schizophrenia (UH3)
Run by The University of Texas Health Science Center, Houston · NCT05276050 · Data updated 2026-11-12
This study tests whether a type of brain stimulation can help people with schizophrenia quit smoking by comparing two different methods.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 22 Years to 65 Years |
| Sex | All |
| Enrollment | 50 (estimated) |
| Sponsor | The University of Texas Health Science Center, Houston Academic / other |
| Locations | 1 site (Houston, Texas) |
| Status | Recruiting |
| Started | June 1, 2022 |
| Main results expected | February 15, 2027 |
| Study ends | February 14, 2028 |
| Registry record updated | September 16, 2026 |
| Trial ID | NCT05276050 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are adults aged 22-65 with a diagnosis of schizophrenia spectrum disorder who have been smoking regularly.
✕Probably not a fit
Patients who do not smoke or have not smoked in the past year may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This study investigates the use of repetitive transcranial magnetic stimulation (rTMS) to aid smoking cessation in patients diagnosed with schizophrenia spectrum disorder. Participants will receive either active rTMS from an F8 coil or an H coil, with their smoking habits and brain connectivity monitored throughout the process. The goal is to target specific brain circuits associated with both nicotine addiction and schizophrenia to enhance treatment efficacy. The study aims to compare the effectiveness of these two rTMS methods in this unique patient population.
Why it matters
Potential benefit: If successful, this approach could significantly improve smoking cessation rates among individuals with schizophrenia, enhancing their overall health and quality of life.
How similar studies have gone: While the use of rTMS for smoking cessation is FDA-cleared for the general population, its efficacy in patients with schizophrenia has not been previously evaluated, making this a novel approach.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Male and female between ages 22-65 years 2. Ability to give written informed consent 3. Smoking in the last one year or more and average cigarette per day ≥ 5 in the past 4 weeks 4. Diagnosed with schizophrenia-spectrum disorder and Evaluation to Sign Consent (ESC) above10. 5. Is currently under the care of a licensed primary care provider or mental healthcare provider (e.g., psychiatrist, psychologist, nurse practitioner, licensed clinical social worker). 6. Agrees to: (a) provide written permission, as requested, to allow any and all forms of communication between the investigators and study staff and any health care provider who currently provides and/or has provided service to the subject within two years of study enrollment; and (b) provide the names and verifiable contact information (name, email and mailing address, mobile and land-line phone number, as applicable) of at least two reliable persons ≥ age 22, who reside within a 30-minute drive of the subject's residence, and whom the research staff is at liberty to contact, as deemed necessary, for the duration of study participation. Exclusion Criteria: 1. Persons with a first-degree relative with inherited epilepsy, seizure disorder, or seizures or persons who answer "yes" to any of the parts (A. - G.) of Question 3 of an epilepsy screening questionnaire. 2. Had smoking cessation treatment, clinical trial, or nicotine replacements within the past four weeks. 3. Significant alcohol or other drug use (substance dependence within 6 months or substance abuse within 1 month) other than nicotine or marijuana dependence. 4. Any major medical illnesses that may affect normal brain functioning. Examples of these conditions include, but not limited to, stroke, CNS infection or tumor, other significant brain neurological conditions. 5. Taking \> 400 mg clozapine/day or Failed TMS screening questionnaire. 6. Cardiac pacemakers, implanted medication pumps, intracardiac lines, or acute, unstable cardiac disease, with intracranial implants (e.g. aneurysm clips, shunts, stimulators, cochlear implants, or electrodes) or any other metal object within or near the head, excluding the mouth, that cannot be safely removed. 7. History of head injury with loss of consciousness over 10 minutes; history of brain surgery 8. Cannot refrain from using alcohol and/or marijuana 24 hours or more \& cigarette smoking one hour or more prior to experiments. 9. Woman who is pregnant (child-bearing potential but not on contraceptive and missing menstrual period; or by self-report; or by positive pregnancy test) or has had unprotected sexual intercourse without birth control in the last 4 weeks. 10. Moderate-High Risk of suicide according to the Columbia - Suicide Severity Rating Scale (C- SSRS) Screen Version - Recent (i.e. answers YES to Question 3 and NO to Question 6 (Moderate risk); or answers YES to Questions 4, 5, or 6 (High risk) or in the clinical judgement of the investigator or the study psychiatrist. 11. In the medical opinion of the investigator, subjects with the following circumstances or conditions which can increase the risk of seizures may be excluded: sleep deprivation; major depressive disorder comorbid with dementia, underweight status; concurrent use of cephalosporins and antiarrhythmics (particularly propranolol); metabolic abnormalities (hyponatremia, hypocalcemia, hypomagnesemia, hypoglycemia, hyperglycemia, renal failure/uremia, liver failure); raised blood concentrations of proconvulsant medications due to reduced clearance (e.g. secondary to initiation of antibiotics for treatment of infections); alcohol withdrawal; use of stimulants, such as cocaine or MDMA; use of immunosuppressive therapy with cyclosporine, tacrolimus and other agents that can cause the posterior reversible leukoencephalopathy syndrome; dialysis; systemic infection, and fever itself.
Where it's running
-
The University of Texas Health Science Center, Houston
Houston, Texas, United States Recruiting
Study contacts
- Principal investigator: Xiaoming Du, PhD — The University of Texas Health Science Center, Houston
- Study coordinator: Xiaoming Du, PhD
- Email: Xiaoming.Du@uth.tmc.edu
- Phone: 443-882-9717
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Quitting Matters: a smoking quit program for people living with HIV
This 6-month program will test whether a tailored smartphone app plus nicotine patches and gum helps people living with HIV quit smoking better than a standard quit app.
-
Using Lumateperone to improve motivation in patients with schizophrenia and psychosis
This study is testing if Lumateperone can help people with schizophrenia or schizoaffective disorders feel more motivated and less apathetic.
-
Examining the effects of combined therapy for schizophrenia
This study is testing whether combining two therapies, one for managing thoughts and another for improving cognitive skills, can help people with schizophrenia do better in their daily lives compared to using just one of the therapies.
-
Smoky Futures: Danish Adolescent Nicotine Use over Time
This observational cohort follows Danish youths ages 15–25 to see how cigarette, e-cigarette, and other nicotine use begin, change, and affect health and education over several years.
-
XEP527 in stable schizophrenia: safety and how it behaves in the body
This small, early-stage study tests the safety and how XEP527 behaves in people with stable schizophrenia who are on a single antipsychotic.
-
Theta-Burst Transcranial Magnetic Stimulation for Treatment-Resistant Auditory Hallucinations
This study tests whether theta-burst transcranial magnetic stimulation can lessen persistent auditory verbal hallucinations in adults with schizophrenia-spectrum or psychotic disorders who have not responded to antipsychotic meds.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.